- Home
- NNY vs DERM Comparison
NNY vs DERM Comparison
Compare NNY & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNY
- DERM
- Stock Information
- Founded
- NNY 1987
- DERM 2014
- Country
- NNY United States
- DERM United States
- Employees
- NNY N/A
- DERM N/A
- Industry
- NNY Investment Managers
- DERM Biotechnology: Pharmaceutical Preparations
- Sector
- NNY Finance
- DERM Health Care
- Exchange
- NNY Nasdaq
- DERM Nasdaq
- Market Cap
- NNY 153.2M
- DERM 165.6M
- IPO Year
- NNY N/A
- DERM 2021
- Fundamental
- Price
- NNY $7.99
- DERM $7.59
- Analyst Decision
- NNY
- DERM Strong Buy
- Analyst Count
- NNY 0
- DERM 1
- Target Price
- NNY N/A
- DERM $9.00
- AVG Volume (30 Days)
- NNY 50.9K
- DERM 198.2K
- Earning Date
- NNY 01-01-0001
- DERM 08-11-2025
- Dividend Yield
- NNY 4.04%
- DERM N/A
- EPS Growth
- NNY N/A
- DERM N/A
- EPS
- NNY N/A
- DERM N/A
- Revenue
- NNY N/A
- DERM $56,243,000.00
- Revenue This Year
- NNY N/A
- DERM $28.99
- Revenue Next Year
- NNY N/A
- DERM $52.61
- P/E Ratio
- NNY N/A
- DERM N/A
- Revenue Growth
- NNY N/A
- DERM N/A
- 52 Week Low
- NNY $7.58
- DERM $3.54
- 52 Week High
- NNY $8.87
- DERM $8.25
- Technical
- Relative Strength Index (RSI)
- NNY 37.77
- DERM 59.81
- Support Level
- NNY $7.99
- DERM $7.05
- Resistance Level
- NNY $8.13
- DERM $7.92
- Average True Range (ATR)
- NNY 0.06
- DERM 0.40
- MACD
- NNY -0.00
- DERM 0.05
- Stochastic Oscillator
- NNY 12.50
- DERM 66.39
About NNY Nuveen New York Municipal Value Fund
Nuveen New York Municipal Value Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from both regular federal and New York state income taxes, by investing in a portfolio of municipal obligations issued by state and local government authorities within the state of New York or certain U.S. territories.
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.